RE:Question for experts here For what I know: Piper Jaffray traget audience was not the financial community but rather more the prospect partner pharmas. It was more a business development event than anything else for Prometic. With tons of one-on-one meeting with the different to-be-partners of the industry.
One must remember two crucial things here.
Both CKD/DKD/ESRD *and* MS-T2D indications are way too big for Prometic to run after alone. (And probably a few more indcations too... NASH, heart comes to mind..) Prometic will need to partner these in the coming Qs...
And Pierre as already repeatedly said straight out that their goal is to fill a matrix of partnerships, with different indications on one axis, and different regions on the other. I suggest this will happen in the really next Qs (there is persistent noise about an early japanese one that could be signed before year end -- I wouldn't bet on that, by experience everything is longer than anticipted in that area).
Now you have to appreciate the scene: all the players are floating around at the conference. They all see each other attending the presentation and then going in private meetings with Pierre one after the other.
Hahaha! :-D
I've witnessed such partnership-event franzy in a previous life and the running buzz is almost vaudevillesque! That's as close as it can be to a public auction. But with Louis XIV style jeux de coulisse and antichamber talks.
I can't wait to see the final outcome, but considering the next steps ahead of PLI, let's say that I can not imagine a better context to reveal those 4050-MS-T2D spectacular preliminary data.
Yesterday's message was definitely aimed at partners, not us or WallStreet.
Now, for the financial community, there's gonna be this "analysts day" Pierre refered to at the last CC. That should be enough to bring them thoroughly up to speed. :-) (Not mentionning dithyrambic if one or two deals are signed by then.)
My 2 cents!
:-)
FD